1[1]Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reaction after bone marrow transplantation [J]. Blood, 1990, 75: 555-562.
2[2]Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphopro-liferative disorders after allogeneic bone marrow transplantation[J]. N Engl J Med,1994, 330: 1185-1191.
3[3]Rooney CM, Smith CA, Ng CYC, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-Virus-related lymphoproliferation[J]. Lancet, 1995, 345: 9-13.
4[4]Naparstek E,Or R, Nagler A, et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor′s peripheral blood lymphocytes for prevention of relapse[J]. Br J Haematol,1995,89:506-515.
5[5]Toze CL, Barnett MJ, Klingemann HG, et al. Response of therapy-related myelodysplasia to low-dose interleukin-2[J]. Leukemia, 1993, 7: 463-465.
6[6]Meloni G, Foa R, Vignetti M, et al. Interleukin-2 may induce prolonged remissons in advanced acute myelogenous leukemia[J]. Blood, 1994, 84: 2158-2163.
7[7]Bergmann L, Heil G, Kolbe K, et al. Interleukin-2 bolus infusion as late consolidation therapy in second remission of acute myeloblastic leukemia[J]. Leukemia Lymphoma, 1995, 16: 271-279.
8[8]Hamon MD, Prentice HG, Gottlieb DJ, et al. Immunotherapy with interleukin-2 after ABMT in AML[J]. Bone Marrow Transpl,1993, 11(5): 399-401.
9[9]Torge EC, Hagop MK, Susan OB, et al. A pilot study of inteleukin-2 for adult patients with acute myelogenous leukemia in first complete remission[J]. Cancer, 1999, 85: 1506-1513.
10[10]Neubauer MA, Benyunes MC, Thompson JA, et al. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation[J]. Bone Marrow Transpl, 1994, 13: 311-316.
